[{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ Themis","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ Themis"},{"orgOrder":0,"company":"ABL Bio","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ABL Bio \/ HiFiBiO Therapeutics"},{"orgOrder":0,"company":"ABL Bio","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ABL111","moa":"CD137 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"ABL301","moa":"IGF-1R","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.0600000000000001,"dosageForm":"","sponsorNew":"ABL Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Sanofi"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"3","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TJ-L14B","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"ABL Bio \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by ABL Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to evaluate ABL103 in combination with MSD's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with advanced or metastatic solid tumors.

                          Brand Name : ABL103

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 04, 2024

                          Lead Product(s) : ABL103,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to develop new bispecific antibody-drug conjugates using Biocytogen’s RenLite® mice platform that can produce fully human antibodies with diverse epitopes and high affinity.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 25, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Biocytogen

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : TJ-L14B/ABL503, is a differentiated PD-L1 x 4-1BB bispecific antibody, which is investigated in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment.

                          Brand Name : ABL503

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 10, 2023

                          Lead Product(s) : TJ-L14B

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : I-Mab Biopharma

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 13, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Synaffix

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration supports the development and manufacturing of ABL Bio’s new bispecific antibody product by leveraging Lonza’s GS Xceed® expression system which includes GS PiggyBac®, a highly efficient transposon-based gene integration technology...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 04, 2023

                          Lead Product(s) : Bispecific Antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Lonza Group

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.

                          Brand Name : ABL301

                          Molecule Type : Large molecule

                          Upfront Cash : $75.0 million

                          January 11, 2022

                          Lead Product(s) : ABL301

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Sanofi

                          Deal Size : $1,060.0 million

                          Deal Type : Collaboration

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The preclinical studies confirmed the unique pharmacodynamic data and safety of TJ-CD4B/ABL111 in animal models and cell cultures and was well tolerated in non-human primates and did not induce a systemic immune response or liver toxicity up to levels of...

                          Brand Name : TJ-CD4B

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 09, 2021

                          Lead Product(s) : ABL111

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : I-Mab Biopharma

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.

                          Brand Name : HFB30132A

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 14, 2020

                          Lead Product(s) : HFB30132A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : HiFiBiO Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Themis and ABL Europe have signed an agreement under which ABL will manufacture Themis' vaccine candidate in preparation for clinical trials.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 11, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Themis Bioscience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank